...
首页> 外文期刊>The Japanese journal of antibiotics >Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2001--II. Gram-negative bacteria
【24h】

Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2001--II. Gram-negative bacteria

机译:在1996年至2001年之间,头孢唑仑对各种临床分离株的抗菌活性逐年变化。革兰氏阴性菌

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates obtained between 1996 and 2001 were yearly evaluated and compared with those of other cephems, oxacephems and carbapenems. A total of 3,245 strains in 32 species of Gram-negative bacteria were isolated from the clinical materials annually collected from January to December, and consisted of Moraxella subgenus Branhamella catarrhalis, Escherichia coli, Citrobacter freundii, Citrobacter koseri, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter aerogenes, Enterobacter cloacae, Serratia marcescens, Proteus mirabillis, Proteus vulgaris, Morganella morganii, Providencia spp. (P. alcalifaciens, P. rettgeri, P. stuartii), Pseudomonas aeruginosa, Pseudomonas putida, Burkholderia cepacia, Stenotrophomonas maltophilia, Haemophilus influenzae, Acinetobactor baumannii, Acinetobactor lwoffii, Bacteroides fragilis group (B. fragilis, B. vulgatus, B. distasonis, B. ovatus, B. thetaiotaomicron), and Prevotella spp. (P. melaninogenica, P. intermedia, P. bivia, P. oralis, P. denticola). CZOP possessed stable antibacterial activities against M. (B.) catarrhalis, E. coli, C. freundii, C. koseri, K. pneumoniae, K. oxytoca, E. aerogenes, E. cloacae, S. marcescens, P. mirabilis, P. vulgaris, M. morganii, Providencia spp., P. aeruginosa, and A. lwoffii throughout 6 years. The MIC90 of CZOP against those strains were consistent with those obtained from the studies performed until the new drug application approval. On the other hand, the MIC90 of CZOP against H. influenzae yearly obviously increased with approximately 64-time difference during the study period. The MIC90 of cefpirome, cefepime, and flomoxef against H. influenzae also yearly tended to rise. The present results demonstrated that CZOP had maintained the antibacterial activity against almost Gram-negative strains tested. However, the decrease in antibacterial activities of CZOP against B. cepacia, and H. influenzae was suggested.
机译:每年评估头孢菌素的一种药物头孢索普兰(CZOP)对1996年至2001年获得的各种临床分离株的体外抗菌活性,并将其与其他头孢菌,草ace和碳青霉烯进行比较。从1月至12月每年收集的临床资料中,共分离出32种革兰氏阴性细菌中的3,245株,其中包括卡他莫拉菌属,布兰氏杆菌,大肠杆菌,弗氏柠檬酸杆菌,科氏柠檬酸杆菌,肺炎克雷伯菌,肠溶克雷伯菌,产气杆菌,阴沟肠杆菌,粘质沙雷氏菌,米氏变形杆菌,寻常变形杆菌,摩根氏摩根氏菌,普罗维登斯菌。 (P. alcalifaciens,P.rettgeri,P.stuartii),铜绿假单胞菌,恶臭假单胞菌,洋葱伯克霍尔德菌,嗜麦芽窄食单胞菌,流感嗜血杆菌,鲍氏不动杆菌,鲍氏不动杆菌,Bacteroides fra。 ,卵形芽孢杆菌,B。thetaiotaomicron)和Prevotella spp。 (P. melaninogenica,P。intermedia,P。bivia,P。oralis,P。denticola)。 CZOP对卡他莫拉氏菌(B.),大肠杆菌,弗氏梭状芽胞杆菌,科氏杆菌,肺炎克雷伯菌,产氧克雷伯菌,产气链球菌,阴沟肠杆菌,marcescens链霉菌,米氏疟原虫,整整6年的时间分别是寻常型毕赤酵母,摩根分枝杆菌,普罗维登斯菌,铜绿假单胞菌和l.offoffii。 CZOP对这些菌株的MIC90与从新药申请获得批准之前进行的研究获得的MIC90一致。另一方面,在研究期间,CZOP对流感嗜血杆菌的MIC90每年明显增加,相差约64倍。头孢哌啶,头孢吡肟和氟莫昔夫对流感嗜血杆菌的MIC90也逐年上升。目前的结果表明,CZOP对测试的几乎所有革兰氏阴性菌株均保持了抗菌活性。但是,建议降低CZOP对洋葱伯克霍尔德杆菌和流感嗜血杆菌的抗菌活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号